Starting with mescaline, we are developing a portfolio of plant-identical psychedelic compounds for FDA approval through a stakeholder model that includes the community of clinicians, non-profits, and Indigenous groups whose work is foundational to the success of this sector.
We're looking to meet with researchers and clinicians who want to develop other plant and natural medicines through a model that combines mission and the ability to scale.
Comments
Starting with mescaline, we are developing a portfolio of plant-identical psychedelic compounds for FDA approval through a stakeholder model that includes the community of clinicians, non-profits, and Indigenous groups whose work is foundational to the success of this sector.
Where are you planning to go from there?
We're looking to meet with researchers and clinicians who want to develop other plant and natural medicines through a model that combines mission and the ability to scale.